All TauroLock™ products contain citrate as an anticoagulant in order to maintain a high flow rate over extended periods of time. At a concentration of 4% as used in these products, citrate safely removes calcium ions from the blood coagulation cascade and thus prevents the coagulation of blood in the catheter and the ensuing impaired patency.
Moreover, TauroLock™ is available supplemented with 100 IU/mL heparin (TauroLock™-Hep100) or 500 IU/mL heparin (TauroLock™-Hep500). The addition of heparin has an additive anticoagulant effect.
The most intense prophylaxis against catheter occlusion and infections is attained through the regular use of TauroLock™-U25.000 (TauroLock™ supplemented with a final concentration of 5,000 IU/mL urokinase). This reduces flow problems in the catheter substantially. The decision as to which catheter lock solution is best suited depends on the situation of the individual patient. An alternating use of the TauroLock™ products, i.e. TauroLock™-Hep500 and TauroLock™-U25.000, is feasible.